Medicinova (MNOV) Current Deferred Revenue (2011 - 2025)

Medicinova (MNOV) posted quarterly Current Deferred Revenue of $370160.0 for Q4 2025, down 29.07% quarter-over-quarter from $521899.0 in Q3 2025.

Medicinova (MNOV) Current Deferred Revenue (2011 - 2025) Analysis & Trends

Medicinova (MNOV) has reported Current Deferred Revenue for 4 consecutive years, with $370160.0 the latest figure, recorded in Q4 2025.

In Q4 2025, Current Deferred Revenue changed N/A year-over-year to $370160.0; the TTM figure through Dec 2025 stood at $370160.0 (changed N/A YoY), while the FY2025 annual figure was $370160.0, changed N/A from the prior year.
Current Deferred Revenue fell to $370160.0 in Q4 2025 per MNOV's latest filing, from $521899.0 in the prior quarter.
Across five years, Current Deferred Revenue topped out at $1.7 million in Q3 2021 and bottomed at $370160.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Medicinova	68.42 Mn	68.42 Mn	317,759.00

Download Data